After signing up, you'll start to receive regular news updates from us.
Genetix Announces Proposed Acquisition of Applied Imaging Corporation
Complete the form below to unlock access to ALL audio articles.
Genetix Group plc has announced that it has signed a definitive agreement to acquire all the issued and to be issued share capital in Applied Imaging Corporation (AI) in an all cash transaction valued at US$18.3m (£9.6m) subject to, amongst other things, approval by AI stockholders.
AI’s audited results for the 12 months ended 31 December 2005 stated revenue of US$20.0m with a loss before tax of US$0.9m; unaudited results for the 6 months ended 30 June 2006 showed revenue of US$9.9m with a loss before tax of US$0.4m. Net assets as at 30 June 2006 were US$3.4m.
The transaction is expected to be completed in the fourth quarter of 2006 subject to, amongst other things, approval by AI’s stockholders. The relevant documentation is expected to be sent to AI stockholders shortly.
The proposed acquisition of AI, which is to be financed entirely through the Company’s existing cash resources (£24.7m as at 30 June 2006 (US$46.9m) (unaudited)), fits well with Genetix’ strategic objective to broaden its competencies in cell imaging and analysis.
Key benefits to the Company of the proposed acquisition are as follows:
- Combining AI’s expertise in cell analysis software with Genetix’ core skills in imaging and analysing cells will strengthen Genetix’ ability to offer a broader range of products in both the drug discovery and clinical diagnostics markets
- Provides an expanded sales force and customer support in the key US market allowing enhanced opportunities for selling and supporting Genetix’ existing products, with corresponding expanded selling opportunities for AI products in UK and Europe
- Over the last 3½ years AI has generated consistent gross margins in excess of 55% with 63% achieved in the six months to 30 June 2006
- Opportunities for cost synergies and operational enhancements
Commenting on the acquisition, Mark Reid, Chief Executive of Genetix said, "Joining together these two respected businesses focused on cell imaging and analysis will help us strengthen our position and exploit the growth opportunities in both the drug discovery and clinical diagnostics markets."
"The expanded product portfolio as well as AI’s strength in the key US market will help with cross-selling opportunities and an improved level of support for our wider customer base."
"We believe that the investment associated with this transaction will enhance shareholder value."
